{"product_id":"glp-3-rt","title":"GLP 3 (RT)","description":"\u003cp\u003eGLP-3 (RT) — a metabolic research material, supplied as a vial with third-party analytical testing and per-batch documentation.\u003c\/p\u003e\u003ch3\u003eAbout GLP 3 (RT)\u003c\/h3\u003e\u003cp\u003eRT (development code LY3437943), marketed by the client as \"GLP-3,\" is a synthetic single-molecule peptide of 39 amino acids engineered as a first-in-class triple incretin receptor agonist. In experimental characterization it activates three class B G-protein-coupled receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its backbone incorporates aminoisobutyric acid (Aib) substitutions and fatty-acid acylation designed to confer protease resistance and extended circulating half-life.\u003c\/p\u003e\u003cp\u003eIn preclinical and in-vitro research, RT has been used to study the pharmacology of combined incretin and glucagon-receptor engagement, including effects on energy metabolism, glucose handling, and adiposity in animal models. Its balanced triple-agonist profile distinguishes it from single (GLP-1R) and dual (GIP\/GLP-1) agonists and has made it a subject of intense metabolic-research interest. This material is supplied strictly for Research Use Only.\u003c\/p\u003e\u003ch3\u003eSpecifications\u003c\/h3\u003e\u003ch4\u003eIdentification\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMaterial:\u003c\/strong\u003e GLP 3 (RT)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAlso searched as:\u003c\/strong\u003e GLP3, GLP 3, RT, LY3437943\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResearch Area:\u003c\/strong\u003e Metabolic Research\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePresentation:\u003c\/strong\u003e Vial\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg · 10mg · 15mg · 30mg\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 2381089-83-2\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C221H342N46O68\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 4731.34 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eType:\u003c\/strong\u003e Synthetic acylated peptide (triple incretin agonist)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReceptor \/ Target:\u003c\/strong\u003e GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePubChem CID:\u003c\/strong\u003e \u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/171934787\" target=\"_blank\" rel=\"noopener\"\u003e171934787\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAmino Acid Sequence\u003c\/h4\u003e\u003cp\u003eY-Aib-QGTFTSDYSILLDKKAQ-Aib-AFIEYLLEGGPSSGAPPPS (39 residues, dual fatty-acid acylated)\u003c\/p\u003e\u003ch4\u003eAnalytical Data\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity (HPLC):\u003c\/strong\u003e ≥99%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity (MS):\u003c\/strong\u003e Confirmed to specification\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesting:\u003c\/strong\u003e Accredited (ISO 17025) third-party laboratory\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCertificate:\u003c\/strong\u003e View COA · Lot 26109001\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eKey Characteristics\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C221H342N46O68\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 4731.34 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 2381089-83-2\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePubChem CID:\u003c\/strong\u003e 171934787\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReceptor \/ Target:\u003c\/strong\u003e GIPR, GLP-1R, and GCGR (triple agonist)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Type:\u003c\/strong\u003e Synthetic 39-residue acylated peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilized powder in vial\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store lyophilized at -20 C to -80 C; protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Lyophilized stable for extended periods frozen\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eResearch Context\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTriple incretin receptor pharmacology —\u003c\/strong\u003e Reference ligand for combined GIPR \/ GLP-1R \/ GCGR activation and signaling studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnergy metabolism research —\u003c\/strong\u003e Model compound for preclinical study of energy expenditure and adiposity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlucose homeostasis —\u003c\/strong\u003e Used in animal and cell-based models of glucose handling and insulin secretion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLong-acting peptide design —\u003c\/strong\u003e Illustrates Aib substitution and fatty-acid acylation strategies for half-life extension.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eResearch Findings\u003c\/h4\u003e\u003cp\u003ePublished preclinical and early-phase research characterizes RT as a balanced agonist across GIPR, GLP-1R, and GCGR, with in-vitro potency data reported for each receptor. In animal models it has been associated with changes in body weight, food intake, and glucose parameters attributed to its combined incretin and glucagon-receptor activity.\u003c\/p\u003e\u003cp\u003eThese observations derive from experimental, preclinical, and early clinical-pharmacology settings and are provided for scientific context only. No human efficacy or therapeutic conclusions are implied by this listing.\u003c\/p\u003e\u003ch4\u003eHistory\u003c\/h4\u003e\u003cp\u003eRT (LY3437943) was developed by Eli Lilly as a triple GIP\/GLP-1\/glucagon receptor agonist, building on the incretin biology established by earlier GLP-1 and dual GIP\/GLP-1 agonists. Coskun and colleagues published its discovery and pharmacology, and it subsequently advanced through clinical evaluation as an investigational metabolic agent.\u003c\/p\u003e\u003ch4\u003eReferences\u003c\/h4\u003e\u003col\u003e\n\u003cli\u003eCoskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control: from discovery to clinical proof of concept. Cell Metabolism.\u003c\/li\u003e\n\u003cli\u003eJastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist RT for Obesity - A Phase 2 Trial. New England Journal of Medicine.\u003c\/li\u003e\n\u003cli\u003eRosenstock J, et al. (2023). RT, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet.\u003c\/li\u003e\n\u003c\/ol\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/171934787\" target=\"_blank\" rel=\"noopener\"\u003eView compound profile on NIH PubChem\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003eCited literature refers to laboratory and preclinical research. GLP 3 (RT) is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.\u003c\/p\u003e\u003ch4\u003eWhy researchers choose Helio\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e99%+ Purity —\u003c\/strong\u003e HPLC-verified every batch\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccredited Testing —\u003c\/strong\u003e Independent ISO 17025 laboratory\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePer-Batch COA —\u003c\/strong\u003e Documentation tied to your lot\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMade in the USA —\u003c\/strong\u003e Discreet, protected shipping\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eFrequently Asked\u003c\/h4\u003e\u003cp\u003e\u003cstrong\u003eAre these research materials third-party tested?\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eYes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhat purity are the materials?\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eMaterials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDo you provide a Certificate of Analysis (COA)?\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eYes. Per-batch COA documentation is provided and is traceable by lot number.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWhere do you ship from?\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eMaterials are shipped from the USA in discreet, protective packaging.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eAre these products for human use?\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eNo. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.\u003c\/p\u003e\u003cp\u003e\u003cem\u003eResearch use only — not for human or animal consumption. Per-batch documentation is provided with the material.\u003c\/em\u003e\u003c\/p\u003e","brand":"heliopeptides","offers":[{"title":"5mg","offer_id":67669937160435,"sku":null,"price":45.47,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":67669937193203,"sku":null,"price":45.47,"currency_code":"USD","in_stock":true},{"title":"15mg","offer_id":67669937225971,"sku":null,"price":58.47,"currency_code":"USD","in_stock":true},{"title":"30mg","offer_id":67669937258739,"sku":null,"price":97.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/8791\/0387\/files\/64c471f9c324.webp?v=1791395015","url":"https:\/\/heliopeptides.com\/products\/glp-3-rt","provider":"Helio Peptides","version":"1.0","type":"link"}